08/20/2026
The IFOPA is pleased to share breaking news-approval of Regeneron's drug in the US! Thanks to all who took part in the trial! 💙💚
💡 Do you know what Pasatru™ is?
It is the brand name for Regeneron's drug garetosmab, which has been approved today in the 🇺🇸 United States to treat FOP.
Pasatru™ (garetosmab) is only the second drug approved for FOP in the U.S., and the first shown to have an impact on both bone growth and flare-ups.
As we announce this decision, we are deeply grateful to people living with FOP from around the world who participated in two pivotal trials of garetsomab: LUMINA-1 Phase 2 and OPTIMA Phase 3 🙌
We also want to thank Regeneron and its employees for their long-standing commitment and dedication to the FOP community. This drug was invented by scientists at Regeneron who were looking for ways to treat FOP by blocking heterotopic bone growth 👏
📌 Learn more and read Regeneron’s press release: ifopa.org/garetosmab-fda-approval
Congratulations to the FOP community on this very special day! 💚💙